Dosimetric study of RapidArc plans with flattened beam (FB) and flattening filter-free (FFF) beam for localized prostate cancer based on physical indices
Purpose: To identify the continual diversity between flattening photon beam (FB) and Flattening Filter Free (FFF) photon beams for localized prostate cancer; and to determine potential benefits and drawbacks of using unflattened beam for this type of treatment.
Methods: Eight prostate cases including seminal vesicles selected for this study. The primary planning target volume (PTVP) and boost planning target volume (PTVB) were contoured. The total prescription dose was 78 Gy (56 Gy to PTVP and an additional 22 Gy to PTVB). For all cases, treatment plans using 6MV with FB and FFF beams with identical dose-volume constraints, arc angles and number of arcs were developed. The dose volume histograms for both techniques were compared for primary target volume and critical structures.
Results: A low Sigma index (FFF: 1.65 + 0.361; FB: 1.725 + 0.39) indicating improved dose homogeneity in FFF beam. Conformity index (FFF: 0.994 + 0.01; FB: 0.993 + 0.01) is comparable for both techniques. Minimal difference of Organ at risk mean dose was observed. Normal tissue integral dose in FB plan resulted 1.5% lower than FFF plan. All the plans displayed significant increase (1.18 times for PTVP and 1.11 for PTBB) in the average number of necessary MU with FFF beam.
Conclusion: Diversity between FB and FFF beam plans were found. FFF beam accelerator has been utilized to develop clinically acceptable Rapid Arc treatment plans for prostate cancer with 6 MV.
Cite this article as: Rout BK, Muralidhar KR, Ali M, Shekar MC, Kumar A. Dosimetric study of RapidArc plans with flattened beam (FB) and flattening filter-free (FFF) beam for localized prostate cancer based on physical indices. Int J Cancer Ther Oncol 2014; 2(4):02046. DOI: 10.14319/ijcto.0204.6
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 2013. Lyon, France: International Agency for Research on Cancer. Available from http://globocan.iarc.fr
Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006; 65:1-7.
Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 2011; 29:1517-24.
Rukstalis DB. Treatment options after failure of radiation therapy-a review. Rev Urol 2002; 4 Suppl 2:S12-7.
Heidenreich A, Bolla M. Joniau S, et al. Guidelines on Prostate Cancer; European Association of Urology 2011
Yoo S, Wu QJ, Lee WR, Yin FF. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes. Int J Radiat Oncol Biol Phys 2010; 76:935-42.
Seppala J, Suilamo S, Kulmala J, et al. A dosimetric phantom study of dose accuracy and build-up effects using IMRT and RapidArc in stereotactic irradiation of lung tumours. Radiat Oncol 2012; 7:79.
Wiant DB, Terrell JA, Maurer JM, Yount CL, Sintay BJ. Commissioning and validation of BrainLAB cones for 6X FFF and 10X FFF beams on a Varian TrueBeam STx. J Appl Clin Med Phys 2013;14:4493.
Georg D, Knoos T, McClean B. Current status and future perspective of flattening filter free photon beams. Med Phys 2011; 38:1280-93.
Sun M, Ma L. Treatment Exceptionally large prostate cancer patients with low energy intensity modulated photons. J Appl Clin Med Phys 2006; 7:43-9.
Orton NP, Tome WA. The impact of daily shifts on prostate IMRT dose distribution. Med Phys 2004; 31:1-4.
Bragg CM, Windate K, Conway J. Clinical implementations of the anisotropic analytical algorithm for IMRT treatment planning and verification. Radiother Oncol 2008; 86:276-84.
Lu, L. Dose calculation algorithms in external beam photon radiation therapy. Int J Cancer Ther Oncol 2013; 1:01025.
Yoon M, Park SY, Shin D, et al. A new homogeneity index based on statistical analysis of the dose-volume histogram. J Appl Clin Med Phys 2007; 8:9-17.
Lawrence BM, Ellen DY, ANDREW J, et al. Use of normal tissue complication probability model in the clinic. Int J Radiat Oncol Biol Phys 2010; 76: S10–S19.
Michalski JM, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Bio Phys 2000; 46:391–402.
Followill D, Geis P, Boyer A. Estimates of whole-body dose equivalent produced by beam intensity modulated conformal therapy. Int J Radiat Oncol Biol Phys 1997; 38:667-72.
Miften MM, Das SK, Su M, Marks LB. A dose-volume based tool for evaluating and ranking IMRT treatment plans. J Appl Clin Med Phys 2004; 5:1-14.
Vassiliev ON, Titt U, Ponisch F, et al. Dosimetric properties of photon beams from a flattening filter free clinical accelerator. Phys Med Biol 2006; 51:1907-17.
Vassiliev ON, Kry SF, Kuban DA, et al. Treatment-planning study of prostate cancer intensity-modulated radiotherapy with a Varian clinic operated without a flattening filter. Int J Radiat Oncol Biol Phys 2007; 68:1567-71.
Stathakis S, Esquivel C, Gutierrez A, et al. Treatment planning and delivery of IMRT using 6and 18MV photon beams without flattening filter. Appl Radiat Isot 2009; 67:1628-37.
Zwahlen DR, Lang S, Hrbacek J, et al. The use of photon beams of a flattening filter-free linear accelerator for hypofractionated volumetric modulated arc therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 83:1655-60.
Aoyama H, Westerly DC, Mackie TR, et al. Integral radiation dose to normal structures with conformal external beam radiation. Int J Radiant Oncol Biol Phys 2006; 64:962-967.
Almond PR, Biggs PJ, Coursey BM, et al. AAPM’s TG-51 protocol for clinical reference dosimetry of high-energy photon and electron beams. Med Phys 1999; 26:1847-70.
Fu W, Dai J, Hu Y, et al. Delivery time comparison for Intensity-modulated radiation therapy with/ without flattening filter: A planning Study. Phys Med Biol 2004; 49:1535-47.
Lang S, Reggiori G, Puxeu Vaquee J, et al. Pretreatment quality assurance of flattening filter free beams on 224 patients for intensity modulated plans; a multicentric study. Med Phys 2012; 39:1351-6.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.